{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:44:57Z","timestamp":1772631897971,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clml.2024.11.006","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T11:53:09Z","timestamp":1731757989000},"page":"258-264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Clinical Features on Survival and Relapse of Patients Diagnosed With T-cell Acute Lymphoblastic Leukemia \u2013 a Multicenter Cohort Study"],"prefix":"10.1016","volume":"25","author":[{"given":"Diego Luz Felipe","family":"da Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6155-3253","authenticated-orcid":false,"given":"Bruno Kosa Lino","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yve Cardoso","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camila","family":"Piaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordana Santos Ramires","family":"Arag\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Cerello","family":"Chapchap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eduarda Alonso Joaquim","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitor Augusto Queiroz","family":"Mauad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9707-0579","authenticated-orcid":false,"given":"Elvira DRP","family":"Velloso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata Lyrio Rafael","family":"Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ires Hamyra Bezerra","family":"Massaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Rodrigues","family":"Kerbauy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo M","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-3181","authenticated-orcid":false,"given":"Wellington F","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.11.006_bib0001","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0002","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome\u2013Negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clml.2024.11.006_bib0003","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","article-title":"Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome\u2013Negative acute lymphoblastic leukemia: A review","volume":"4","author":"Siegel","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2024.11.006_bib0004","first-page":"3346","article-title":"Acute lymphoblastic leukemia immunotherapy treatment: now","volume":"15","author":"Aureli","year":"2023","journal-title":"Next, and Beyond, Cancers"},{"key":"10.1016\/j.clml.2024.11.006_bib0005","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood-2002-01-0110","article-title":"Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia","volume":"99","author":"Hoelzer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0006","first-page":"396","article-title":"Adult acute lymphoblastic leukemia in a resource-constrained setting: outcomes after expansion of genetic evaluation","volume":"27","author":"Silva","year":"2022","journal-title":"Hematol. Amst. Neth."},{"key":"10.1016\/j.clml.2024.11.006_bib0007","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clml.2014.03.004","article-title":"Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia","volume":"15","author":"Portugal","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clml.2024.11.006_bib0008","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/j.clml.2018.03.001","article-title":"Treating adult acute lymphoblastic leukemia in Brazil-increased early mortality using a German Multicenter Acute lymphoblastic leukemia-based regimen","volume":"18","author":"da Silva Junior","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clml.2024.11.006_bib0009","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL)","volume":"9","author":"Bene","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.11.006_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.11.006_bib0011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood.V110.11.12.12","article-title":"Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07\/2003","volume":"110","author":"G\u00f6kbuget","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0012","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0013","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clml.2024.11.006_bib0014","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-lineage adult acute lymphoblastic leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.clml.2024.11.006_bib0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood.V114.22.324.324","article-title":"Successful subtype oriented treatment strategies in adult T-all; results of 744 patients treated in three consecutive GMALL studies","volume":"114","author":"Hoelzer","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0016","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0017","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.leukres.2006.08.004","article-title":"Clinical features and outcome of T-lineage acute lymphoblastic leukemia in adults: a low initial white blood cell count, as well as a high count predict decreased survival rates","volume":"31","author":"Yanada","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clml.2024.11.006_bib0018","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2022-158381","article-title":"Results of the risk-adapted, MRD-stratified GMALL trial 08\/2013 in 281 T-ALL \/T-lbl patients: excellent outcome of standard risk thymic T-ALL","volume":"140","author":"Goekbuget","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0019","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/cancers14030565","article-title":"Characteristics and outcome of elderly patients (>55 Years) with acute lymphoblastic leukemia","volume":"14","author":"Wenge","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2024.11.006_bib0020","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1182\/bloodadvances.2023011661","article-title":"A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study","volume":"8","author":"Enshaei","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.11.006_bib0021","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/s41375-024-02264-0","article-title":"Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols","volume":"38","author":"Neumann","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.11.006_bib0022","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/asheducation-2016.1.573","article-title":"Treatment of older patients with acute lymphoblastic leukemia","volume":"2016","author":"G\u00f6kbuget","year":"2016","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2024.11.006_bib0023","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2023-179562","article-title":"Nelarabine (NEL), Pegylated Asparginase (PEG) and Venetoclax (VEN) incorporated to HCVAD chemotherapy in the frontline treatment of adult patients with T-cell acute lymphoblastic leukemia\/lymphoblastic lymphoma (T-ALL\/T-LBL)","volume":"142","author":"Senapati","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0024","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1182\/blood-2023-177696","article-title":"Frontline consolidation with Nelarabine for adults with high-risk T-cell acute lymphoblastic leukemia. Results of the Graall-2014\/T Atriall phase 2 study","volume":"142","author":"Boissel","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0025","unstructured":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial - PubMed, (n.d.). https:\/\/pubmed.ncbi.nlm.nih.gov\/15353542\/(accessed August 27, 2024)."},{"key":"10.1016\/j.clml.2024.11.006_bib0026","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2005-04-1754","article-title":"Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol","volume":"107","author":"Vitale","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0027","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ejh.12269","article-title":"High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden","volume":"92","author":"Kozlowski","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.clml.2024.11.006_bib0028","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2021-152355","article-title":"First analysis of the UKALL14 randomized trial to determine whether the addition of Nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK\/09\/006)","volume":"138","author":"Rowntree","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.006_bib0029","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood-2023-190141","article-title":"Risk-adjusted therapies yield equivalent outcomes for adolescents and young adults (AYAs) treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) on children's oncology group (COG) studies AALL0434 and AALL1231","volume":"142","author":"Colace","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:40:10Z","timestamp":1772606410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2152265024024170"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Clinical Features on Survival and Relapse of Patients Diagnosed With T-cell Acute Lymphoblastic Leukemia \u2013 a Multicenter Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}